This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ruiz, L. Articles by Wang, Y.-M. Search for Related Content PubMed PubMed Citation Articles by Ruiz, L. Articles by Wang, Y.-M.

Auditory Function in Pediatric Osteosarcoma Patients Treated with Multiple Doses of cis-Diamminedichloroplatinum(II)

Division of Pediatrics and Division of Head and Neck Surgery, University of Texas, M. D. Anderson Hospital and Tumor Institute, Houston, Texas 77030

Serial auditory evaluations were performed in 54 pediatric patients (5 to 18 yr) treated with cis-diamminedichloroplatinum(II) for osteosarcoma. Each course of cis-diamminedichloroplatinum(II) comprised 150 mg/m² and was administered initially at two weekly intervals for seven courses (3 mo) and subsequently at three monthly intervals for 15 to 21 mo. Overall, 604 courses were administered, and observations were conducted from diagnosis to 6 yr. Bilateral hearing loss was detected in all patients. The loss varied from mild (20 to 40 dB) to profound (>90 dB). Initial losses occurred in the higher frequencies and were also greater at these frequencies. Significant loss was first observed after 300 mg/m² for frequencies over 4000 Hz and gradually shifted to incorporate the lower frequencies. Hearing loss was permanent.

Received 2/29/88. Revised 10/13/88. Accepted 11/ 2/88.

This article has been cited by other articles:

				W. H. Meyer, C. B. Pratt, C. A. Poquette, B. N. Rao, D. M. Parham, N. M. Marina, A. S. Pappo, H. H. Mahmoud, J. J. Jenkins, J. Harper, et al. Carboplatin/Ifosfamide Window Therapy for Osteosarcoma: Results of the St Jude Children's Research Hospital OS-91 Trial J. Clin. Oncol., January 1, 2001; 19(1): 171 - 182. [Abstract] [Full Text] [PDF]